Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2025-Results-Achieves-2025-Financial-Guidance-and-Reiterates-Strong-2026-Outlook/default.aspx
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-to-Host-Fourth-Quarter-and-Full-Year-2025-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2026/Ironwood-Pharmaceuticals-Maintains-FY-2025-Financial-Guidance-and-Announces-FY-2026-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-Strong-Third-Quarter-2025-Results-Raises-Full-Year-2025-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2025-Results-Maintains-Full-Year-2025-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reports-First-Quarter-2025-Results/default.aspx
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-to-Participate-in-The-Citizens-Life-Sciences-Conference/default.aspx
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Reiterates-Full-Year-2025-LINZESS-U-S–Net-Sales-Guidance-and-Raises-Adjusted-EBITDA-Guidance/default.aspx
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-to-Present-Real-World-Data-at-Digestive-Disease-Week-2025-on-Adoption-of-New-Diagnosis-Codes-Among-Short-Bowel-Syndrome-Patients-Who-Are-Dependent-on-Parenteral-Support/default.aspx
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
https://investor.ironwoodpharma.com/press-releases/press-release-details/2025/Ironwood-Pharmaceuticals-Provides-Clinical-and-Regulatory-Update-on-Apraglutide/default.aspx